NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Evolus, Inc. (EOLS) Stock Analysis

Evolus, Inc. (EOLS) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

EOLS

$9.30

+$0.25 (+2.76%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EOLS with… →

EOLS Key Statistics

As of Sep 4, 2026
Trading
Open
$9.05
Previous Close
$9.05
Day's Range
8.98–9.31
52-Week Range
3.86–9.31
Volume
684.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.43
Valuation
Market Cap
$614.27M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
33.70
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.94
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.54
Financials (FY)
Revenue (FY)
$297.18M+11.61%
Net Income (FY)
−$51.64M
Profit marginThe share of revenue left as profit after all costs and taxes.
−10.85%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
66.05M
1-Year Return
+23.83%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
898.51K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EOLS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+39.85%
2025−39.76%
2024+4.84%
2023+40.21%
2022+15.36%
2021+93.75%
2020−72.39%
2019+2.27%
2018 (partial year)+3.48%

As of September 4, 2026.

EOLS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$297.18M−$51.64M−17.4%
2024$266.27M−$50.42M−18.9%
2023$202.09M−$61.69M−30.5%
2022$148.62M−$74.41M−50.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$297.18M$197.11M−$37.60M−$51.64M−17.4%
2024$266.27M$182.30M−$27.24M−$50.42M−18.9%
2023$202.09M$137.57M−$44.98M−$61.69M−30.5%
2022$148.62M$89.77M−$59.58M−$74.41M−50.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EOLS Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricEOLSDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio1.942.3015% below
Profit margin−10.85%−3.14%7.7 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Evolus, Inc. (EOLS) at $614.27M. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 353.

The 52-week range on file runs from $3.86 to $9.31. EOLS last closed at $9.30 on September 4, 2026. That is +$0.25 (+2.76%) against the previous close. The latest close sits 140.93% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $297.18M. Against the prior fiscal year total of $266.27M, that is a change of +11.61%. The same year closed with a net loss of $51.64M. The reported profit margin is −10.85%. That is 7.7 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.54.

Across the 4 fiscal years on file, revenue moves from $148.62M in 2022 to $297.18M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 33.7. Measured against sales, the shares trade at 1.94 times revenue. On price-to-sales that is 15.48% below the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year price return is +23.83%. Measured over 5 years, that is −0.67% a year compounded. The reported beta is 1.43. Daily returns over the trailing 8 years annualize to a volatility of 76.41%.

Growth & Income

No dividend is on file for EOLS.

Across the complete calendar years on file, 2021 returned +93.75% and 2020 returned −72.39%. Of the 7 complete calendar years on file, 5 finished higher. 2026 is still running; the price is +39.85% year to date.

Peer Comparison

Evolus, Inc. (EOLS) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Evolus, Inc. EOLS $614.27M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Evolus, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Evolus, Inc.

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Visit website →